Christoph Strohhofer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christoph Strohhofer has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Berghold
Institute for Medical Informatics, Statistics, and Documentation, Medical University of Graz, 8036 Graz, Austria
2 shared publications - Andreas Kainz
Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, 8010 Graz, Austria
2 shared publications - Andreas Zirlik
Department of Internal Medicine, Division of Cardiology, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria
2 shared publications - Dirk von Lewinski
Department of Internal Medicine, Division of Cardiology, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria
2 shared publications - Friederike von Lewinski
Interdisciplinary Metabolic Medicine Trials Unit, Medical University of Graz, 8010 Graz, Austria
2 shared publications - Harald Sourij
Medizinische Universitat Graz
2 shared publications
Latest Publications
- Open Access
- 9 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (12) , 4455
Erythrocyte and Platelet Indices at Admission and Discharge Stratify Long-Term Cardiovascular Risk After Invasive Treatment of Myocardial Infarction
Background/Objectives: Cardiovascular risk remains substantial after myocardial infarction (MI) despite established clinical risk markers. Erythrocyte and platelet indices are routinely available, but their long-term prognostic relevance remains insufficiently studied. Methods: This retrospective cohort study was based on the Styrian Registry on Genuine Myocardial Infarction (STRONG-MI) and included patients with MI undergoing invasive coronary angiography in Styria, Austria, between January 2007 and March 2016. Multivariable Cox regression models were used to assess the associations of admission and discharge erythrocyte and platelet indices with 3-point major adverse cardiovascular events (MACE) during follow-up extending to 175 months. Results: Among 10,920 patients, admission hemoglobin showed a U-shaped association with MACE. Median hemoglobin decreased from admission to discharge (14.2 g/dL vs. 13.1 g/dL) and the lowest discharge tertile showed the highest association with MACE compared with the middle tertile (AHR 1.27, 95% CI 1.18–1.38). Lower mean corpuscular hemoglobin concentration (MCHC) was independently linked to adverse outcomes at both admission and discharge (AHR 1.17, 95% CI 1.08–1.27, and 1.14, 95% CI 1.05–1.23, respectively). Higher platelet count and mean platelet volume (MPV) were also associated with increased risk, particularly at discharge (AHR 1.15, 95% CI 1.06–1.24, and 1.19, 95% CI 1.10–1.29, respectively). Conclusions: Routine erythrocyte and platelet indices were independently associated with long-term cardiovascular outcomes after invasively treated MI and reflect residual biological risk after discharge.
- 9 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (12) , 4455
Open AccessErythrocyte and Platelet Indices at Admission and Discharge Stratify Long-Term Cardiovascular Risk After Invasive Treatment of Myocardial Infarction
Background/Objectives: Cardiovascular risk remains substantial after myocardial infarction (MI) despite established clinical risk markers. Erythrocyte and platelet indices are routinely available, but their long-term prognostic relevance remains insufficiently studied. Methods: This retrospective cohort study was based on the Styrian Registry on Genuine Myocardial Infarction (STRONG-MI) and included patients with MI undergoing invasive coronary angiography in Styria, Austria, between January 2007 and March 2016. Multivariable Cox regression models were used to assess the associations of admission and discharge erythrocyte and platelet indices with 3-point major adverse cardiovascular events (MACE) during follow-up extending to 175 months. Results: Among 10,920 patients, admission hemoglobin showed a U-shaped association with MACE. Median hemoglobin decreased from admission to discharge (14.2 g/dL vs. 13.1 g/dL) and the lowest discharge tertile showed the highest association with MACE compared with the middle tertile (AHR 1.27, 95% CI 1.18–1.38). Lower mean corpuscular hemoglobin concentration (MCHC) was independently linked to adverse outcomes at both admission and discharge (AHR 1.17, 95% CI 1.08–1.27, and 1.14, 95% CI 1.05–1.23, respectively). Higher platelet count and mean platelet volume (MPV) were also associated with increased risk, particularly at discharge (AHR 1.15, 95% CI 1.06–1.24, and 1.19, 95% CI 1.10–1.29, respectively). Conclusions: Routine erythrocyte and platelet indices were independently associated with long-term cardiovascular outcomes after invasively treated MI and reflect residual biological risk after discharge.
- 8 June 2026
- Published by American Diabetes Association in Diabetes Care
- Vol. 49 (8) , 1374-1379
Enzymatic 2-Hydroxybutyrate Measurement for Dysglycemia Screening Beyond Conventional Fasting Measures
OBJECTIVE: We investigated whether fasting 2-hydroxybutyrate (2-HB), measured by a novel enzymatic assay (XpressGT), can provide incremental discrimination of dysglycemia beyond routine fasting measures. RESEARCH DESIGN AND METHODS: Associations of 2-HB with dysglycemia were assessed in the total Biomarkers of Personalized Medicine cohort and in the prespecified subcohort with fasting plasma glucose (FPG) <110 mg/dL and HbA1c 140 mg/dL during oral glucose tolerance testing). A sensitivity of 90% was achieved at 39 µmol/L, with a negative predictive value of 98.9%. Each 1-SD increase in 2-HB was independently associated with dysglycemia (odds ratio 2.23; P < 0.001). CONCLUSIONS: Enzymatic 2-HB measurement may serve as a screening biomarker to rule out postprandial dysglycemia in individuals with normal FPG and HbA1c.
- 8 June 2026
- Published by American Diabetes Association in Diabetes Care
- Vol. 49 (8) , 1374-1379
Enzymatic 2-Hydroxybutyrate Measurement for Dysglycemia Screening Beyond Conventional Fasting Measures
OBJECTIVE: We investigated whether fasting 2-hydroxybutyrate (2-HB), measured by a novel enzymatic assay (XpressGT), can provide incremental discrimination of dysglycemia beyond routine fasting measures. RESEARCH DESIGN AND METHODS: Associations of 2-HB with dysglycemia were assessed in the total Biomarkers of Personalized Medicine cohort and in the prespecified subcohort with fasting plasma glucose (FPG) <110 mg/dL and HbA1c 140 mg/dL during oral glucose tolerance testing). A sensitivity of 90% was achieved at 39 µmol/L, with a negative predictive value of 98.9%. Each 1-SD increase in 2-HB was independently associated with dysglycemia (odds ratio 2.23; P < 0.001). CONCLUSIONS: Enzymatic 2-HB measurement may serve as a screening biomarker to rule out postprandial dysglycemia in individuals with normal FPG and HbA1c.
- 26 February 2026
- Published by Elsevier in Journal of Cardiology Cases
- Vol. 33 (5) , 160-163
Thrombocytosis-associated ticagrelor non-responder status after ECMO-supported primary PCI in STEMI
- 26 February 2026
- Published by Elsevier in Journal of Cardiology Cases
- Vol. 33 (5) , 160-163
Thrombocytosis-associated ticagrelor non-responder status after ECMO-supported primary PCI in STEMI
- Open Access
- 2 December 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (23) , 7324
Air Pollution and Myocardial Infarction—A New Smoker’s Paradox?
Background/Objectives: Ambient air pollution is a significant public health concern, known to affect cardiovascular health adversely. Research has identified both long-term and short-term cardiovascular risks associated with various air pollutants, including those linked to acute coronary syndromes. However, the observed effects are rather small, with most data sourced from highly polluted regions. Methods: This study utilized a prospective registry database, documenting 12,581 myocardial infarction (MI) events in Styria, Austria from January 2007 to December 2015. Pollutants analyzed included particulate matter (PM2.5, PM10) and gases, such as NO2, CO, SO2, O3 and NOx. We employed generalized linear models to examine the interaction of each of these pollutants on the daily incidence of MI. Additionally, we conducted separate analyses for patients with specific comorbidities: diabetes mellitus (DM), arterial hypertension (HTN), heart failure with reduced ejection fraction (HFrEF), chronic obstructive pulmonary disease (COPD) and current smokers. Results: No significant associations were identified between any of the pollutants and MI incidence, both in the overall cohort and in patient subgroups with DM, HTN, HFrEF or COPD. However, among active smokers, we observed a decreased relative risk of MI associated with elevated levels of NO2, CO, SO2 and NOx on the day of MI (p < 0.01 for all pollutants). Conversely, an increased MI risk was associated with rising ozone levels (p = 0.0027). This counterintuitive finding aligns with previously published data and may suggest a new dimension to the “smoker’s paradox”. Conclusions: In regions with low pollution levels, air pollutants pose only minor or insignificant short-term risks for myocardial infarction. Active smokers exhibit an altered response to ambient air pollution.
- 2 December 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (23) , 7324
Open AccessAir Pollution and Myocardial Infarction—A New Smoker’s Paradox?
Background/Objectives: Ambient air pollution is a significant public health concern, known to affect cardiovascular health adversely. Research has identified both long-term and short-term cardiovascular risks associated with various air pollutants, including those linked to acute coronary syndromes. However, the observed effects are rather small, with most data sourced from highly polluted regions. Methods: This study utilized a prospective registry database, documenting 12,581 myocardial infarction (MI) events in Styria, Austria from January 2007 to December 2015. Pollutants analyzed included particulate matter (PM2.5, PM10) and gases, such as NO2, CO, SO2, O3 and NOx. We employed generalized linear models to examine the interaction of each of these pollutants on the daily incidence of MI. Additionally, we conducted separate analyses for patients with specific comorbidities: diabetes mellitus (DM), arterial hypertension (HTN), heart failure with reduced ejection fraction (HFrEF), chronic obstructive pulmonary disease (COPD) and current smokers. Results: No significant associations were identified between any of the pollutants and MI incidence, both in the overall cohort and in patient subgroups with DM, HTN, HFrEF or COPD. However, among active smokers, we observed a decreased relative risk of MI associated with elevated levels of NO2, CO, SO2 and NOx on the day of MI (p < 0.01 for all pollutants). Conversely, an increased MI risk was associated with rising ozone levels (p = 0.0027). This counterintuitive finding aligns with previously published data and may suggest a new dimension to the “smoker’s paradox”. Conclusions: In regions with low pollution levels, air pollutants pose only minor or insignificant short-term risks for myocardial infarction. Active smokers exhibit an altered response to ambient air pollution.